NeuroScientific Biopharmaceuticals has secured key backing from the Food and Drug Administration (FDA) for its phase two StemSmart trial for refractory Crohn's disease, supporting a planned year-end start. The regulator gave positive feedback on six of seven questions, including trial design, existing human data and product release testing. The company is addressing the remaining manufacturing control requirement, with trial initiation subject to regulatory, manufacturing and operational requirements.